Comparison of Financial Metrics and Investment Value of Amgen and Johnson & Johnson
JNJ Johnson & Johnson
$263.81 -1.42%
View chart & analysis → - 1Amgen recorded revenue of approximately $36.7 billion in fiscal year 2025.
- 2Johnson & Johnson revenue was approximately $94.2 billion in fiscal year 2025, a 6% increase from the previous year.
- 3Amgen shows low valuation multiples, while Johnson & Johnson possesses a strong balance sheet and higher free cash flow.
So what's the key point?
Amgen and Johnson & Johnson recorded revenues of $36.7 billion and $94.2 billion, respectively. Amgen's stock price appears cheap relative to its earnings, but Johnson & Johnson is generating more cash.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.